You have 9 free searches left this month | for more free features.

rituximab

Showing 1 - 25 of 2,320

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Rituximab in Children With Blood Diseases

Not yet recruiting
  • Rituximab
  • +2 more
  • Rituximab
  • Rituximab (once a week)
  • (no location specified)
Apr 8, 2022

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Trial in Houston (Rituximab, Zanubrutinib)

Recruiting
  • Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
  • Houston, Texas
    M D Anderson Cancer Center
Jul 9, 2022

Recurrent DLBCL, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma Trial in Houston (other, drug,

Recruiting
  • Recurrent Diffuse Large B-Cell Lymphoma
  • +3 more
  • Laboratory Biomarker Analysis
  • +3 more
  • Houston, Texas
    M D Anderson Cancer Center
Jul 26, 2022

Burkitt Lymphoma, KSHV-associated Multicentric Castleman Disease, DLBCL Trial in Kampala (Rituximab and Hyaluronidase Human,

Recruiting
  • Burkitt Lymphoma
  • +2 more
  • Rituximab and Hyaluronidase Human
  • +8 more
  • Kampala, Uganda
    UCI-Fred Hutch Cancer Centre
Mar 9, 2022

Recurrent DLBCL, Recurrent Follicular Lymphoma, Refractory DLBCL Trial in Seattle (Laboratory Biomarker Analysis, Pembrolizumab,

Active, not recruiting
  • Recurrent Diffuse Large B-Cell Lymphoma
  • +3 more
  • Laboratory Biomarker Analysis
  • +3 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Jul 20, 2022

Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma Trial in

Recruiting
  • Recurrent B-Cell Non-Hodgkin Lymphoma
  • +13 more
  • Polatuzumab Vedotin
  • +3 more
  • Scottsdale, Arizona
  • +11 more
Aug 23, 2022

CCND1 Positive, CCND2 Positive, CCND3 Positive Trial in Houston (drug, other, biological)

Active, not recruiting
  • CCND1 Positive
  • +6 more
  • Houston, Texas
    M D Anderson Cancer Center
Jan 11, 2022

Aggressive B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage III Grade 2 Follicular Lymphoma, Ann Arbor Stage III Grade 3 Follicular

Recruiting
  • Aggressive B-Cell Non-Hodgkin Lymphoma
  • +19 more
  • CD47 Antagonist ALX148
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Aug 9, 2022

Double-Expressor Lymphoma, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, High Grade B-Cell Lymphoma

Not yet recruiting
  • Double-Expressor Lymphoma
  • +3 more
  • Sacramento, California
    University of California Davis Comprehensive Cancer Center
Oct 27, 2022

Pharmacological Action Trial (Rituximab, Dexamethasone)

Not yet recruiting
  • Pharmacological Action
  • (no location specified)
Sep 22, 2022

Waldenstrom Macroglobulinemia Trial (Venetoclax; Rituximab, DRC)

Not yet recruiting
  • Waldenstrom Macroglobulinemia
  • Venetoclax; Rituximab
  • DRC
  • (no location specified)
Jul 27, 2022

Ann Arbor Stage II Follicular Lymphoma, Ann Arbor Stage II Marginal Zone Lymphoma, Ann Arbor Stage III Follicular Lymphoma Trial

Active, not recruiting
  • Ann Arbor Stage II Follicular Lymphoma
  • +9 more
  • Houston, Texas
    M D Anderson Cancer Center
Feb 3, 2022

B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Recurrent B Acute

Not yet recruiting
  • B Acute Lymphoblastic Leukemia
  • +2 more
  • Portland, Oregon
    OHSU Knight Cancer Institute
Apr 4, 2022

Refractory Myasthenia Gravis, Rituximab Trial in Guangzhou (Rituximab)

Recruiting
  • Refractory Myasthenia Gravis
  • Rituximab
  • Rituximab
  • Guangzhou, China
    First Affiliated Hospital, Sun Yat-Sen University
Apr 26, 2022

Ann Arbor Stage I Grade 1 Follicular Lymphoma, Ann Arbor Stage I Grade 2 Follicular Lymphoma, Ann Arbor Stage II Grade 1

Active, not recruiting
  • Ann Arbor Stage I Grade 1 Follicular Lymphoma
  • +9 more
  • Quality-of-Life Assessment
  • +2 more
  • Rochester, Minnesota
    Mayo Clinic in Rochester
Feb 3, 2022

Steroid-Dependent Nephrotic Syndrome Trial in Kolkata (Rituximab, Mycophenolate Mofetil)

Active, not recruiting
  • Steroid-Dependent Nephrotic Syndrome
  • Rituximab
  • Mycophenolate Mofetil
  • Kolkata, West Bengal, India
    Nilratan Sircar Medical College and Hospital
Apr 6, 2022

Untreated Mantle Cell Lymphoma Trial in Suzhou (zanubrutinib and rituximab, BEAM pretreatment, zanubrutinib maintenance)

Recruiting
  • Untreated Mantle Cell Lymphoma
  • zanubrutinib and rituximab
  • +2 more
  • Suzhou, Jiangsu, China
    the First Affiliated Hospital of Soochow University
Aug 16, 2022

Idiopathic Membranous Nephropathy Trial (Rituximab, Cyclophosphamide)

Not yet recruiting
  • Idiopathic Membranous Nephropathy
  • (no location specified)
Aug 22, 2022

Recurrent DLBCL, Refractory DLBCL Trial in Sacramento (Chimeric Antigen Receptor T-Cell Therapy, Cyclophosphamide, Fludarabine

Recruiting
  • Recurrent Diffuse Large B-Cell Lymphoma
  • Refractory Diffuse Large B-Cell Lymphoma
  • Chimeric Antigen Receptor T-Cell Therapy
  • +3 more
  • Sacramento, California
    University of California Davis Comprehensive Cancer Center
Mar 8, 2022

Mantle Cell Lymphoma Trial in Saint Louis (Bendamustine, Rituximab, Acalabrutinib)

Active, not recruiting
  • Mantle Cell Lymphoma
  • Saint Louis, Missouri
    Washington University School of Medicine
Feb 2, 2022

Non-Hodgkin Lymphoma Trial in Cologne (Tafasitamab, Lenalidomide, Rituximab)

Not yet recruiting
  • Non-Hodgkin Lymphoma
  • Cologne, Germany
    University of Cologne
Oct 14, 2022

B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative Trial in Seattle (procedure, drug, biological)

Not yet recruiting
  • B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative
  • Bone Marrow Aspiration and Biopsy
  • +7 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Jul 11, 2022

Primary Immune Thrombocytopenia (ITP) Trial (Combination of Rituximab with subcutaneous belimumab, Combination of Rituximab with

Not yet recruiting
  • Primary Immune Thrombocytopenia (ITP)
  • Combination of Rituximab with subcutaneous belimumab
  • Combination of Rituximab with subcutaneous placebo
  • (no location specified)
Apr 15, 2022

Hairy Cell Leukemia Trial in La Jolla (Low dose vemurafenib plus rituximab)

Recruiting
  • Hairy Cell Leukemia
  • Low dose vemurafenib plus rituximab
  • La Jolla, California
    Scripps MD Anderson Cancer Center
May 19, 2022

Mantle Cell Lymphoma Trial in Seoul (RB/RBAC alternating, RB)

Not yet recruiting
  • Mantle Cell Lymphoma
  • RB/RBAC alternating
  • RB
  • Seoul, Gangnam-Gu, Korea, Republic of
    Samsung Medical Center
Apr 18, 2022